Having successfully navigated a two-day, virtual advisory committee review of cancer drug pediatric development plans, the US Food and Drug Administration is ready to embark on its first application-specific virtual meeting, with the oncology panel once again serving as a test bed.
On 14 July, the Oncologic Drugs Advisory Committee will meet via an online teleconferencing platform to discuss GlaxoSmithKline PLC’s belantamab mafodotin, the agency announced in a Federal Register